Randy Sweis to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications Randy Sweis has written about Programmed Cell Death 1 Receptor.
Connection Strength
2.054
-
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer. 2018 04 04; 6(1):24.
Score: 0.554
-
Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacol Res. 2017 Jun; 120:1-9.
Score: 0.515
-
Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. Urol Oncol. 2016 12; 34(12):556-565.
Score: 0.503
-
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell Rep. 2024 May 28; 43(5):114141.
Score: 0.211
-
Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer. JAMA Oncol. 2019 05 01; 5(5):743.
Score: 0.149
-
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8.
Score: 0.122